Page last checked
Glucagon/GLP-1 dual receptor agonist (investigational) · dosing
Survodutide dosage: what the trials studied
The published trial tested 0.6–4.8 mg once weekly (phase 2 arms: 0.6, 2.4, 3.6 or 4.8 mg, reached by up to 20 weeks of escalation). It enrolled 387 participants and ran as the 46-week phase 2 dose-finding trial (20-week escalation + 26-week maintenance). Survodutide has no approved dosing label. The registry records 4 active regimens. Those are randomized study regimens, not a schedule for personal use.
Source: le Roux CW et al. Glucagon and GLP-1 receptor dual agonist survodutide for obesity: dose-finding phase 2 trial. Lancet Diabetes Endocrinol 2024 (PMID 38330987)
What matters first
The published trial dosing program
These are the once-weekly dose groups used in the published trial. The table prints only the dose detail the source supplies. They describe a randomized protocol under monitoring, not a recommended titration schedule.
| Arm | Once-weekly dose | Position in the studied range | How the trial reached it |
|---|---|---|---|
| 1 | 0.6 mg | Lowest arm studied | — |
| 2 | 2.4 mg | Intermediate arm | — |
| 3 | 3.6 mg | Intermediate arm | — |
| 4 | 4.8 mg | Highest arm studied | highest arm |
Source: le Roux CW et al. Glucagon and GLP-1 receptor dual agonist survodutide for obesity: dose-finding phase 2 trial. Lancet Diabetes Endocrinol 2024 (PMID 38330987) · retrieved 2026-08-20 · the paths above reproduce only the doses the source names. The source does not turn those paths into advice.
| Target-dose group | Mean change at 46 weeks | How the paper reports it |
|---|---|---|
| 0.6 mg weekly | 6.2% decrease | Target-dose group |
| 2.4 mg weekly | 12.5% decrease | Target-dose group |
| 3.6 mg weekly | 13.2% decrease | Target-dose group |
| 4.8 mg weekly | 14.9% decrease | highest arm |
| Placebo | 2.8% decrease | Placebo group |
Source: le Roux CW et al. Glucagon and GLP-1 receptor dual agonist survodutide for obesity: dose-finding phase 2 trial. Lancet Diabetes Endocrinol 2024 (PMID 38330987) · retrieved 2026-08-20. Only outcomes the cited paper reports for a named arm appear here; no missing result is estimated.
Why there is no Survodutide dosage chart
A dosage chart is a regulatory artifact before it is an editorial one. It exists when an agency has reviewed a sponsor’s trials, agreed a schedule, and bound the manufacturer to a product of stated identity and potency. Survodutide has none of that yet.
One trial cannot prove long-term safety or show that the result applies to everyone. The highest dose tested is a study dose, not a target for personal use.
FDA has not approved survodutide, also called BI 456906.
Phase 3 SYNCHRONIZE trials study obesity. A separate phase 2 program studies MASH, a form of liver disease. No dosing label exists, and any product sold today is unapproved.
The doses here describe study groups, not advice.
Sites that publish a titration chart for a compound at this stage have built it by inference. They take a trial’s target dose and reverse-engineer a plausible ramp toward it. The result looks exactly like a supported schedule and should not be read as one. The table shows only the trial arms that were actually studied.
3Reference details
Which syringe barrel the units are read on
A unit is not a unit. A U-100 and a U-50 barrel both print 0.01 mL per graduation; a U-40 barrel prints 0.025 mL. The same printed number therefore measures 2.5× the volume on a U-40. That is why every unit figure on this page names its barrel. It is also why a unit count copied from someone else’s syringe means nothing on its own.
| Barrel | Capacity | One graduation | 0.5 mL reads as |
|---|---|---|---|
| U-100 insulin syringe · 1 mL · lines every 2 units | 1 mL | 0.010 mL | 50 units |
| U-100 insulin syringe · 0.5 mL · lines every 1 unit | 0.5 mL | 0.010 mL | 50 units |
| U-40 insulin syringe · 1 mL · lines every 1 unit | 1 mL | 0.025 mL | 20 units |
Barrel capacities and graduation spacing are the printed scales this site’s calculator measures against, not estimates. Three barrels carry only two scales: a U-50 is a half-length U-100, so it reads identically per unit and simply runs out sooner.
What one graduation is worth at each concentration
Reconstitution fixes a concentration, and the concentration fixes what a single graduation carries — before anyone decides what to draw. Below is every pairing of this page’s vial sizes and water volumes, as a concentration and as the mass one U-100 graduation holds at it. No dose is implied by any cell; it is division.
| Vial | + 1 mL water | + 2 mL water |
|---|---|---|
| 5 mg | 5 mg/mL50 mcg per unit | 2.5 mg/mL25 mcg per unit |
| 10 mg | 10 mg/mL100 mcg per unit | 5 mg/mL50 mcg per unit |
Vial strengths and water volumes are the Survodutide record’s own presets. One U-100 graduation is 0.01 mL, so the mass it carries is the concentration times that volume. That is the entire reason the same milligram figure produces a different unit count in every row.
How dosing works in this class
Why the dose escalates instead of starting where it ends
The dose climbs in steps for one reason: how well people tolerate it, not how well it works. The receptors that produce the effect you want are the same ones that slow your stomach down, and your gut reacts hardest when the exposure is new. Hold it steady and the reaction fades. Stepping up gradually is a way of using that — each step is a stretch of time for your body to settle at where it is before the next increase arrives.
The length of each step matters. Shortening it moves the next increase into a period when the body may not have adjusted. Labels and trial plans state the intervals that were tested. A faster ramp was not tested.
Why trial dose groups are not a dosing schedule
A dose-finding trial is an experiment about doses, not a recommendation of one. Its arms exist to spread people across a range so researchers can see the shape of the curve. Some arms are set deliberately low, where too little effect is expected. Others are set high, where people are expected to struggle. Reading the top arm as the target gets the design backwards: the reason for running the whole range was that nobody yet knew which part of it was right.
Trial doses came with screening, monitoring, a set schedule and drug of tested strength and purity. Removing a milligram figure from those conditions removes much of what made it meaningful. The table therefore shows what researchers tested, not a schedule to follow.
Concentration changes the units, not the dose
The dose and the syringe draw are two different things. The dose is a mass in milligrams. The draw is a volume in syringe units. It depends on the concentration after mixing. Adding more bacteriostatic water changes the unit reading, but not the dose.
This matters because a unit count copied from someone else’s vial means nothing without their concentration. That mismatch is the most common way a self-injected dose ends up ten times off. The arithmetic is fixed and safe to state as fact. The dose you apply it to is a clinical decision, and it is not.
Compounded vial?
No approved Survodutide product exists, so nothing here describes one. The calculator does arithmetic only: it converts a milligram figure and a reconstitution into a volume and a unit count, and it takes no position on which figure belongs in the box.
Open the Survodutide calculator →Questions about Survodutide dosing
What are the typical Survodutide dosages?
The trial ran 4 once-weekly regimens between 0.6 mg and 4.8 mg for 46 weeks. An arm is a group a protocol assigned, not a dosage anybody settled on. These are study regimens, not an approved dosing schedule.
How fast can the Survodutide dose increase?
The trial ran as a 46-week phase 2 dose-finding trial (20-week escalation + 26-week maintenance). The page’s own description is once weekly (phase 2 arms: 0.6, 2.4, 3.6 or 4.8 mg, reached by up to 20 weeks of escalation). Nothing published here establishes what a faster ramp would produce.
What if side effects make the next step too hard?
The next increase is optional, not automatic. The label allows a longer stay at the current step when needed. A clinician decides what happens after a dose is hard to handle; the schedule alone cannot make that decision.
Does the starting Survodutide dose treat the condition?
Yes. One randomized group received 0.6 mg once weekly for 46 weeks and the group changed by an average of -6.2% by week 46. That proves the dose was studied; it does not make it an approved starting dose or a recommendation.
What is the highest Survodutide dose on the page?
The highest arm studied was 4.8 mg once weekly. It is simply the highest amount the trial tested. It is not a maximum dose, because no regulator has set one.
Does a compounded vial change the schedule?
No. The dose is a mass in milligrams and comes from the source; the draw is a volume in syringe units and comes from dividing that mass by the concentration reconstitution produced. Adding more bacteriostatic water to the same vial changes every unit figure and changes no dose at all. That is also why a unit count copied from someone else’s vial means nothing without their concentration.
Why do some compounds here have a chart and others do not?
Because a chart is a claim about provenance, not a formatting choice. Where an FDA-approved label specifies a schedule, this site quotes it row by row and cites the label under the table. Where no label exists, the guide shows what trials tested and says plainly that it is not a schedule. For Survodutide, that is the 46-week phase 2 dose-finding trial (20-week escalation + 26-week maintenance) above.
Where to go next on Survodutide
Survodutide side effects, as the sources describe them
The generic calculator behind the survodutide one
Survodutide vs tirzepatide, with the survodutide page in full
Where survodutide sits among the dose schedules
What the FDA has published on survodutide
Where survodutide sits among the source-checked pages